# Ambrosia Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ambrosia-biosciences

- Industry: Biotechnology
- Headquarters: Boulder, US
- Website: www.ambrosiabiosciences.com
- Total disclosed funding: $116M
- Latest round: Series B (Mar 31, 2026)
- Investors on record: 8

## About

Based in Colorado, US, and founded in 2024, Ambrosia Biosciences Inc. operates as a biotechnology company that offers drugs. The company was founded by its president, Nick Traggis. The company founded by Nick Traggis.  In March 2026, Ambrosia Biosciences Inc. raised USD 100 million in series B funding co-led by Blue Owl, Deep Track Capital, and Redmile Group, with participation from Samsara BioCapital, Janus Henderson Investors, BVF Partners, and Boulder Ventures.

Ambrosia Biosciences develops small molecule-based therapies for obesity and other metabolic disorders.

The company plans to use the March 2026 funding to advance its oral small-molecule GLP-1 candidate into a Phase 1 clinical trial and to continue development of other cardiometabolic programs, including GIP and amylin candidates.

## Funding rounds

- Series B, Mar 31, 2026, $100M — Boulder Ventures, Janus Henderson Investors, Redmile Group, BVF Partners, Samsara BioCapital, Blue Owl, Deep Track Capital
- Series A, Jul 23, 2024, $16M — Boulder Ventures, BVF Partners, Merck KGaA

## Investors

- Boulder Ventures (https://capitalatlas.ai/funds/boulder-ventures) — Series A, Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A, Series B
- Merck KGaA — Series A
- Janus Henderson Investors — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B